Deng Yu'en, Fu Ting, Gao Dian, Zhou Jianming, Nie Xinhua, Wang Fenfen, Yu Qiongfang
Department of Gastroenterology and Hepatology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China.
Huankui Academy, Jiangxi Medical College, Nanchang University, Nanchang, 330031, People's Republic of China.
Int J Gen Med. 2025 Jan 30;18:483-496. doi: 10.2147/IJGM.S495692. eCollection 2025.
Crohn's disease (CD) is a chronic inflammatory disorder with periods of exacerbation and remission. We aim to evaluate the systemic immune-inflammation index (SII) as a prognostic biomarker in CD and its utility in predicting disease activity and severity.
This retrospective study analyzed CD patients using the Harvey-Bradshaw index (HBI) for disease stratification and the Simple Endoscopic Score for Crohn's Disease (SES-CD) for post-treatment evaluation. Data analysis was conducted using R software. Serological indices underwent predictive analysis through the receiver operating characteristic (ROC) curve. The least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression identified independent prognostic factors to construct nomograms. Model validation was performed using the Concordance index (C-index), calibration analysis and decision curve analysis (DCA).
In this study, 254 patients with Crohn's disease (CD) were enrolled, including 171 males and 83 females, with ages ranging from 13 to 74. SII was significantly elevated in active CD (p<0.001), correlating with disease severity (p<0.001). Although SII decreased in patients with mucosal healing (p<0.001), its prognostic accuracy (AUC=0.719) was lower than other biomarkers. However, SII emerged as an independent predictor for CD activity and severity with higher efficacy (AUC=0.774 and 0.807). The CD activity and severity prediction nomograms showed high C-indices (0.8038 and 0.8208), indicating strong predictive performance.
SII is a valuable biomarker for assessing CD severity and monitoring mucosal healing post-treatment. The SII-based nomograms offer a reliable model for evaluating CD progression, aiding in personalized treatment approaches and enhancing clinical decision-making. We recommend randomized controlled trials (RCTs) or studies with larger sample sizes to improve the model.
克罗恩病(CD)是一种具有病情加重期和缓解期的慢性炎症性疾病。我们旨在评估全身免疫炎症指数(SII)作为CD的预后生物标志物及其在预测疾病活动度和严重程度方面的效用。
这项回顾性研究使用哈维-布拉德肖指数(HBI)对CD患者进行疾病分层,并使用克罗恩病简易内镜评分(SES-CD)进行治疗后评估。使用R软件进行数据分析。通过受试者工作特征(ROC)曲线对血清学指标进行预测分析。采用最小绝对收缩和选择算子(LASSO)回归及多变量逻辑回归确定独立的预后因素以构建列线图。使用一致性指数(C指数)、校准分析和决策曲线分析(DCA)进行模型验证。
本研究纳入了254例克罗恩病(CD)患者,其中男性171例,女性83例,年龄在13至74岁之间。活动期CD患者的SII显著升高(p<0.001),与疾病严重程度相关(p<0.001)。虽然黏膜愈合患者的SII有所下降(p<0.001),但其预后准确性(AUC=0.719)低于其他生物标志物。然而,SII成为CD活动度和严重程度的独立预测指标,效能更高(AUC=0.774和0.807)。CD活动度和严重程度预测列线图显示出较高的C指数(0.8038和0.8208),表明预测性能较强。
SII是评估CD严重程度和监测治疗后黏膜愈合的有价值的生物标志物。基于SII的列线图为评估CD进展提供了可靠的模型,有助于个性化治疗方案的制定并加强临床决策。我们建议开展随机对照试验(RCT)或更大样本量的研究以改进该模型。